Literature DB >> 8364207

Lysis of human monocytic leukemia cells by extracellular adenosine triphosphate: mechanism and characterization of the adenosine triphosphate receptor.

E Spranzi1, J Y Djeu, S L Hoffman, P K Epling-Burnette, D K Blanchard.   

Abstract

The present study shows that extracellular adenosine triphosphate (ATP) has the capacity to mediate dose-dependent lysis of the monocytic leukemia cell line THP-1. The lysis, assessed by 51Cr release, was found to be selective for ATP, because adenosine diphosphate (ADP) or other nucleotides were less effective in their ability to lyse the cells. The amount of 51Cr released was particularly enhanced by the stimulation of the cells with 1,000 U/mL of interferon gamma (IFN-gamma) for 3 days, and the sensitivity was time and dose dependent. Analysis of the mechanism of lysis indicated that the fully ionized form, ATP4-, mediated the lysis, because the addition of cation chelators or the absence of the divalent cations, Ca2+ and Mg2+, in the culture medium of a 6-hour 51Cr release assay increased the percent specific lysis. Therefore, the ATP receptors on THP-1 cells were classified as P2Z purinoceptors. Moreover, it is shown here that the Ca2+/calmodulin complex plays a role in the regulation of the lysis by extracellular ATP of THP-1 cells, because antagonists of this complex, such as trifluoperazine or KN-62, were found to inhibit the ATP-mediated cell lysis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364207

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 2.  Adenosine triphosphate: established and potential clinical applications.

Authors:  H J Agteresch; P C Dagnelie; J W van den Berg; J H Wilson
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

3.  Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer.

Authors:  C M Haskell; E Mendoza; K M Pisters; F V Fossella; R A Figlin
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 4.  P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy.

Authors:  Alba Clara Sarti; Valentina Vultaggio-Poma; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2021-04-05       Impact factor: 3.765

5.  The therapeutic potential of adenosine triphosphate as an immune modulator in the treatment of HIV/AIDS: a combination approach with HAART.

Authors:  Marc C E Wagner
Journal:  Curr HIV Res       Date:  2011-06       Impact factor: 1.581

Review 6.  P2X7 is a cytotoxic receptor….maybe not: implications for cancer.

Authors:  Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2020-10-04       Impact factor: 3.765

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.